

Thorsten H Ecke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2771705/publications.pdf>

Version: 2024-02-01

79
papers

1,206
citations

394421

19
h-index

414414

32
g-index

82
all docs

82
docs citations

82
times ranked

1917
citing authors

#	ARTICLE	IF	CITATIONS
1	Nomograms including the UBC [®] Rapid test to detect primary bladder cancer based on a multicentre dataset. <i>BJU International</i> , 2022, 130, 754-763.	2.5	6
2	Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5620.	4.1	0
3	Exploring solid-phase proximity ligation assay for survivin detection in urine. <i>PLoS ONE</i> , 2022, 17, e0270535.	2.5	1
4	Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7898.	4.1	5
5	Identifying the Molecular Mechanisms Contributing to Progression, Metastasis, and Death in Low-grade Non-muscle-invasive Bladder Cancer: A Case Report. <i>European Urology Open Science</i> , 2021, 27, 29-32.	0.4	2
6	Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11547.	4.1	16
7	Molecular identification of telomerase reverse transcriptase (TERT) promoter mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 77.e17-77.e25.	1.6	12
8	Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol. <i>Advances in Therapy</i> , 2020, 37, 592-602.	2.9	10
9	EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. <i>Oncogene</i> , 2020, 39, 6856-6870.	5.9	31
10	SWI/SNF Alterations in Squamous Bladder Cancers. <i>Genes</i> , 2020, 11, 1368.	2.4	3
11	Establishment and Characterization of an Empirical Biomarker SS/PV-ROC Plot Using Results of the UBCA [®] Rapid Test in Bladder Cancer. <i>Entropy</i> , 2020, 22, 729.	2.2	4
12	Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6034.	4.1	17
13	Evaluating the Utility of Combined Bladder Cancer Biomarkers, the Molecular Prognostication of Tumor Subtypes, or What Else Is Needed to Illuminate Our Vision?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9657.	4.1	0
14	Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7420.	4.1	2
15	Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. <i>BMC Cancer</i> , 2020, 20, 230.	2.6	24
16	Illumination of a Vision 2020 – Urinary Based Biomarkers for Bladder Cancer on the Way to Clinical Decisions – Dream or Nightmare?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1694.	4.1	3
17	Health-related quality of life and rates of toxicity after high-dose-rate brachytherapy in combination with external beam radiation therapy for high-risk prostate cancer. <i>Investigative and Clinical Urology</i> , 2020, 61, 250.	2.0	1
18	Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. <i>Frontiers in Genetics</i> , 2019, 10, 1237.	2.3	43

#	ARTICLE	IF	CITATIONS
19	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 423-431.	1.6	16
20	UBC ^Â ® Rapid Test ^Â ” A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3841.	4.1	21
21	Evaluation of a New Survivin ELISA and UBC ^Â ® Rapid for the Detection of Bladder Cancer in Urine. <i>International Journal of Molecular Sciences</i> , 2018, 19, 226.	4.1	23
22	Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1622.	4.1	6
23	Human amniotic membrane dressing for the treatment of an infected wound due to an entero-cutaneous fistula: Case report. <i>International Journal of Surgery Case Reports</i> , 2018, 51, 11-13.	0.6	15
24	Protocol for a Randomized Phase II Trial for Mesh Optimization by Autologous Plasma Coating in Prolapse Repair: IDEAL Stage 3. <i>Advances in Therapy</i> , 2017, 34, 995-1006.	2.9	3
25	Successful evacuation of large perirenal hematoma after extracorporeal shock wave lithotripsy (ESWL) â€”step 1 of the IDEAL recommendations of surgical innovation. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 123-125.	0.5	6
26	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA) <i>Tj ETQq0 0 0 rgBT / Overlock 40 Tf 50 45</i>		
27	Registry of implants for the reconstruction of pelvic floor in males and females: A feasibility case series. <i>International Journal of Surgery</i> , 2017, 42, 27-33.	2.7	3
28	UBC ^Â ® Rapid Test for detection of carcinoma in situ for bladder cancer. <i>Tumor Biology</i> , 2017, 39, 101042831770162.	1.8	28
29	Human Amniotic Membrane Is Not Suitable for the Grafting of Colon Lesions and Prevention of Adhesions in a Xenograft Rat Model. <i>Surgical Innovation</i> , 2017, 24, 313-320.	0.9	5
30	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. <i>Scientific Reports</i> , 2017, 7, 12682.	3.3	16
31	Transvesical Suprapubic Externalization of Ureteral Stents - Introduction of a Surgical Innovation at the Development Stage. <i>Urologia Internationalis</i> , 2017, 99, 69-76.	1.3	3
32	miR ^Â 199a ^Â 3p and miR ^Â 214 ^Â 3p improve the overall survival prediction of muscle ^Â invasive bladder cancer patients after radical cystectomy. <i>Cancer Medicine</i> , 2017, 6, 2252-2262.	2.8	31
33	Retrospective analysis of a surgical innovation using the IDEAL framework: radical cystectomy with epidural anaesthesia. <i>Journal of International Medical Research</i> , 2017, 45, 714-722.	1.0	6
34	Quality of life and pain relief in men with metastatic castration ^Â resistant prostate cancer on cabazitaxel: the non ^Â interventional â€”QoLiTime ^Â ™ study. <i>BJU International</i> , 2017, 119, 731-740.	2.5	3
35	Evidence in Urologic- and Pelvic-Surgery Research: Finding the IDEAL Way of Reporting. <i>BioMed Research International</i> , 2017, 2017, 1-2.	1.9	0
36	Bladder Reconstruction with Human Amniotic Membrane in a Xenograft Rat Model: A Preclinical Study. <i>International Journal of Medical Sciences</i> , 2017, 14, 310-318.	2.5	24

#	ARTICLE	IF	CITATIONS
37	Illumination of a Visionâ€”How Arthur Rimbaud Will Give Us Motivation to Find New Input into Bladder Cancer Biomarker Research. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2463.	4.1	2
38	Presentation of a method at the Exploration Stage according to IDEAL: Percutaneous nephrolithotomy (PCNL) under local infiltrative anesthesia is a feasible and effective method - retrospective analysis of 439 patients. <i>International Journal of Medical Sciences</i> , 2017, 14, 302-309.	2.5	11
39	Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma1. <i>Bladder Cancer</i> , 2016, 2, 341-349.	0.4	7
40	Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1879.	4.1	4
41	Repair of a vesico-vaginal fistula with amniotic membrane â€” Step 1 of the IDEAL recommendations of surgical innovation. <i>Central European Journal of Urology</i> , 2015, 68, 459-61.	0.3	19
42	Urinary thiosulfate as failed prostate cancer biomarker â€” an exemplary multicenter re-evaluation study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 477-83.	2.3	7
43	Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 293-316.	1.6	7
44	Impact of obesity in patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 346-346.	1.6	0
45	Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer. <i>Anticancer Research</i> , 2015, 35, 2651-5.	1.1	17
46	Clinical and pathological features of metastatic adenocarcinoma of the prostate to the ileum. <i>Central European Journal of Urology</i> , 2014, 67, 357-60.	0.3	1
47	Evaluating the Use of Prostate-Specific Antigen as an Instrument for Early Detection of Prostate Cancer beyond Urologists: Results of a Representative Cross-Sectional Questionnaire Study of General Practitioners and Internal Specialists. <i>Urologia Internationalis</i> , 2014, 93, 160-169.	1.3	3
48	Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 48.e1-48.e8.	1.6	10
49	Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e15-30.e21.	1.6	14
50	Metastatic penile carcinoma â€” an update on the current diagnosis and treatment options. <i>Central European Journal of Urology</i> , 2014, 67, 126-32.	0.3	35
51	The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 346-352.	1.9	21
52	Relationship between 6â€”and 9â€”month progressionâ€”free survival and overall survival in patients with metastatic urothelial cancer treated with firstâ€”line cisplatinâ€”based chemotherapy. <i>Cancer</i> , 2013, 119, 3020-3026.	4.1	9
53	Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatinâ€”based chemotherapy. <i>Cancer</i> , 2013, 119, 3012-3019.	4.1	82
54	Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. <i>Anti-Cancer Drugs</i> , 2013, 24, 422-425.	1.4	29

#	ARTICLE	IF	CITATIONS
55	Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.. Journal of Clinical Oncology, 2013, 31, 256-256.	1.6	5
56	We need to know the treatment urethral injuries. Central European Journal of Urology, 2013, 66, 359-60.	0.3	0
57	Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer.. Journal of Clinical Oncology, 2013, 31, 251-251.	1.6	0
58	Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer.. Journal of Clinical Oncology, 2013, 31, 269-269.	1.6	0
59	External Validation of an Artificial Neural Network and Two Nomograms for Prostate Cancer Detection. ISRN Urology, 2012, 2012, 1-6.	1.5	8
60	Targeted agents in second-line bladder cancer therapy. Anti-Cancer Drugs, 2012, 23, 1003-1015.	1.4	10
61	Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 139-144.	1.6	9
62	Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.. Journal of Clinical Oncology, 2012, 30, 4524-4524.	1.6	11
63	KISS1 Methylation and Expression as Tumor Stratification Biomarkers and Clinical Outcome Prognosticators for Bladder Cancer Patients. American Journal of Pathology, 2011, 179, 540-546.	3.8	44
64	Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma. Anti-Cancer Drugs, 2011, 22, 9-17.	1.4	11
65	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. Clinical Chemistry, 2010, 56, e1-e48.	3.2	184
66	Tumormarker beim Blasentumor: Aussichten für den klinischen Alltag / Tumor markers for bladder cancer: outlook for routine use. Laboratoriums Medizin, 2010, 34, 77-86.	0.6	0
67	Evaluation of Symptoms and Patients' Comfort for JJ-ureteral Stents With and Without Antireflux-membrane Valve. Urology, 2010, 75, 212-216.	1.0	26
68	Nephrocutaneous Bypass in Ureteral Obstruction. Urology, 2010, 76, 480-485.	1.0	11
69	TP53 gene mutations in prostate cancer progression. Anticancer Research, 2010, 30, 1579-86.	1.1	54
70	DISCOVERY OF THE METHYLATION OF THE METASTASIS SUPPRESSOR GENE, KISS-1, IN BLADDER CANCER. Journal of Urology, 2009, 181, 374-374.	0.4	2
71	Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World Journal of Urology, 2008, 26, 243-250.	2.2	39
72	Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 470-473.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaire. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 474-478.	1.6	40
74	TP53 gene mutations as an independent marker for urinary bladder cancer progression. <i>International Journal of Molecular Medicine</i> , 2008, 21, 655-61.	4.0	28
75	Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. <i>Oncology Reports</i> , 2006, 16, 1381-8.	2.6	14
76	Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. <i>Anticancer Research</i> , 2005, 25, 635-41.	1.1	19
77	Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. <i>Anticancer Research</i> , 2003, 23, 957-62.	1.1	4
78	TP53 gene mutations as an independent marker for urinary bladder cancer progression. <i>International Journal of Molecular Medicine</i> , 0, , .	4.0	5
79	Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. <i>Oncology Reports</i> , 0, , .	2.6	4